Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia (CAH) is a rare genetic disorder that affects the body’s ability to create and regulate adrenal steroid hormones. It results from a genetic mutation that prevents the adrenal glands from producing cortisol. Adrenal glands are walnut-sized organs which sit on top of your kidneys.

The Study

  • The study is evaluating Tildacerfont, an investigational, non-steroid tablet that seeks to treat CAH. Tildacerfont aims to treat the disease by improving the control of adrenal steroid hormones, possibly reducing the likelihood of long-term effects of the disease.

Qualified Participants

  • Men and women between the ages of 18 to 55 years old
  • Have a documented diagnosis of classic CAH due to 21-hydroxylase deficiency
  • Have been on a stable daily dose of steroids (glucocorticoids and/or mineralocorticoid) prior to starting the trial
  • Must meet additional criteria

If Qualified & you Participate you will Receive;

  • Study-related care at no cost
  • Insurance is not required
  • Compensation for time and travel is available

Enroll In This Study Today

Please list any studies you are interested in

Make an appointment and we’ll contact you.